Abstract: Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB, and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.

Abstract: Compounds according to Formula 1, devices containing the same and formulations containing the same are described. Formula 1 has the following structure: where at least two of R1-R10 are not H, where at least one of R1-R10 has the formula T1 where L is an organic linker, where Y1 to Y4 are CR or N, where adjacent R moieties can form fused rings, where Rs and Rt are independently aryl or heteroaryl, either of which may independently be further substituted, and where Rs and Rt do not form fused rings with any part of the molecule.

Abstract: Compounds according to Formula 1, devices containing the same and formulations containing the same are described. Formula 1 has the following structure: where at least two of R1-R10 are not H, where at least one of R1-R10 has the formula T1 where L is an organic linker, where Y1 to Y4 are CR or N, where adjacent R moieties can form fused rings, where Rs and Rt are independently aryl or heteroaryl, either of which may independently be further substituted, and where Rs and Rt do not form fused rings with any part of the molecule.

Abstract: Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB, and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.

Abstract: The present disclosure provides novel compounds containing dibenzo[fg,op]tetracene and larger all-benzenoid moiety that can be used as hosts for phosphorescent emitters providing low-voltage, high-efficiency and high-stability devices.

Abstract: Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB, and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.

Abstract: Novel compounds, and in particular, novel molecules having twisted aryl groups are provided. In particular, the compounds include an aryl group at the ortho position relative to an amine nitrogen, thereby causing a twist within the compound from the plane of the aryl group due to the steric effect. As a result, this decreases the tendency of the molecules to pack closely and results in a higher solid state triplet energy due to reduced solid state ?-stacking. Additionally, organic light emitting devices (OLEDs) comprising a layer including these novel compounds are provided.

Abstract: Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB, and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.

Abstract: Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazoles of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.

Abstract: Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB, and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.

Abstract: Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazoles of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.

Abstract: Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB, and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.